Our Company

Our Company

Corporate Responsibility

Corporate Responsibility

Disclosures

Leadership

Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core.
Learn more

At Seqirus, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.
Learn more
Expertise

Expertise

Influenza

Influenza

Pandemic Response Solutions

Antivenom & Q fever Vaccines

In-licensing

Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.
Learn more

Seqirus is on the front line of battling influenza, working hard to suppress costly and life-threatening epidemics and pandemics. Vaccination is the most effective way to prevent influenza .
Learn more
R&D

R&D

Research Practices

Investigator Initiated Studies

Our Seqirus research and development group provides support to ensure the conditions are optimised for efficient vaccine manufacture. Activities also focus on improving the effectiveness of current influenza vaccines and their manufacturing processes.
Learn more

At Seqirus, we are committed to carrying out R&D in an ethical and transparent way as well as in accordance with government regulations and industry codes for good practice.
Learn more
Manufacturing

Manufacturing

Global Manufacturing Network

Technologies

Technical Development

Quality & Safety

One of the largest influenza vaccine companies in the world, Seqirus operates state-of-the-art manufacturing facilities in three different continents and a globally integrated supply chain for the timely supply of influenza vaccine to customers around the world.
Learn more

Seqirus utilises both egg and cell-based production technologies and we offer a broadest portfolio of influenza vaccines. We have commercialised the only adjuvanted seasonal influenza vaccine for older adults and paediatrics and offer two different types of quadrivalent influenza vaccines.
Learn more
Products
Careers

Careers

See Yourself at Seqirus

Discover Our People

Diversity and Inclusion

How we care for you at Seqirus

When you join Seqirus, you join a team dedicated to protecting people and communities from influenza. It's a feeling of purpose and possibility that inspires us every day.
Learn more

It doesn't matter whether you are a scientist or an administrator, a marketer or an operator - as long as you are inspired by the chance to create something that will help others, you can find your role at Seqirus.
Learn more

Our Company
- Corporate Responsibility
Expertise
- Influenza
R&D
Manufacturing
Careers

Popular search terms:

Search Results Label

71 results found

Seqirus | About Influenza

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.com/expertise/influenza
Seqirus | Influenza Expertise

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-receives-canadian-approval
Seqirus | Latest News

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/new-data-demonstrate-that-fluad-reduces-hospitalization-risk-for-adults-65
Seqirus Releases First Shipment for 2019 2020 Season

Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.

https://www.seqirus.com/news/seqirus-releases-first-shipment-for-2019-2020-season
Seqirus Presents New Clinical Data Reinforcing MF59

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-presents-new-clinical-data-reinforcing-mf59
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses

Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses

https://www.seqirus.com/news/seqirus-presents-scientific-data-comparing-circulating-influenza-b-viruses
Fluad Tetra CHMP

Positive EMA CHMP Positive Opinion for Fluad Tetra

https://www.seqirus.com/news/fluad-tetra-chmp
Seqirus opens new Centre of Excellence in Amsterdam

Seqirus opens new Centre of Excellence in Amsterdam

https://www.seqirus.com/news/seqirus-opens-new-centre-of-excellence-in-amsterdam
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-begins-shipping-2017-2018-influenza-vaccines

Popular search terms:

Corporate

CSL Limited (Global)

Seqirus